reply to @JdmoneyMy apologies, "unreasonably" is probably too...

reply to @Jdmoney

My apologies, "unreasonably" is probably too strong a term.

I understood that the Ex US value for cardioprotection anticancer is arrived at by doubling the US number and then allowing a bit more upside for increased anthracycline use exUS. The use exUS is 95% (not 60% or 70%).

Also any underestimation made in the US market is carried over into the Global valuation. The US assumes 25% reduction in anthracycline use over the next 10 years, all the reports I found on the global doxorubicin market expect a CAGR of around 6% over the next 5 - 10 years.

My point is that I agree with others who have mentioned the Triangle report is conservative and I haven't seen anything yet to refute LTs valuations.

If I have misunderstood the Triangle report or are making incorrect assumptions, more than happy to be corrected.